XSHE
003020
Market cap578mUSD
Oct 09, Last price
17.30CNY
1D
2.00%
1Q
-7.68%
IPO
-20.20%
Name
Hefei Lifeon Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a wide array of pharmaceutical goods. Its product portfolio encompasses active pharmaceutical ingredients (APIs) such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate. The company also manufactures various medicinal preparations, including felodipine sustained-release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablets, yiqihewei capsules, kunning granules, armillariella oral solution, paeonol ointment, urea and vitamin E cream, Kecuo Yintong gel, and Compound Golden Larch bark gel. Additionally, Hefei Lifeon Pharmaceutical supplies plant extracts like clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. Beyond its manufacturing operations, the company operates a retail chain for pharmaceuticals. Established in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. is headquartered in Hefei, China.
Key people
Xiaojuan Deng
Vice Chairman of the Board · since 2023
Yi Liu
Chief Financial Officer · since 2025
Tianhe Dai
Deputy General Manager · since 2022
Shaobing Gou
Deputy General Manager · since 2025
Yong Zheng
Deputy General Manager · since 2025
Jun Xia
Deputy General Manager, Secretary of tjhe Board · since 2018
Junqu Ji
Chairman of the Board · since 2010
Tiecheng Ji
Deputy General Manager, Director · since 2025
Jinhua Li
Independent Director · since 2022
Jing Shi
Independent Director · since 2023
Morong Yang
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||